Treatment response and short-term outcomes in children admitted as multisystem inflammatory syndrome in children

IF 0.1 Q4 MEDICINE, GENERAL & INTERNAL
M. Batt, G. Saini, M. Dar
{"title":"Treatment response and short-term outcomes in children admitted as multisystem inflammatory syndrome in children","authors":"M. Batt, G. Saini, M. Dar","doi":"10.4103/jss.jss_210_22","DOIUrl":null,"url":null,"abstract":"Background: Multisystem inflammatory syndrome in children (MIS-C) is a postviral complication that has been described among children after 2–6 weeks of exposure to the COVID-19 virus from various parts of the world. Published literature regarding MIS-C in children is limited. The aim of this study was to investigate the disease management and clinical outcomes of a larger group of children from North India presenting with features of MIS-C. Materials and Methods: This is an observational study of children with MIS-C, admitted to the pediatric intensive care unit (PICU) between March 1, 2021, and August 31, 2021, during the second wave of SARS-CoV-2 infection in India. Results: Out of the 37 children presenting with MIS-C, 62% of patients were male and 37% were female patients. Vasoactive medications were required in 14 patients. Eighteen patients required respiratory support, of which 17 received noninvasive ventilation and only one patient required invasive mechanical ventilation. Methylprednisolone and intravenous immunoglobulin (IVIG) were used in the majority of patients. No patient required remdesivir. Thirty-six patients were discharged home with a median duration of 4 days in PICU and a hospital stay of 10 days, only 1 (2.7%) patient died during the treatment. Thirty-five (94.5%) patients received IVIG alone, and five patients (13.5%) received IVIG along with methylprednisolone. Patients who received a combination of steroids and IVIG had greater severity of illness, deranged laboratory parameters, highly raised inflammatory markers, requiring higher inotropes, respiratory support, PICU requirement, and length of stay in hospital. Conclusions: The decision to treat MIS-C patients with IVIG plus methylprednisolone or IVIG alone must be reviewed on an individual basis. IVIG in conjunction with methylprednisolone should be considered for patients with severe MIS-C and hypotension who have been admitted to the PICU.","PeriodicalId":55681,"journal":{"name":"Journal of the Scientific Society","volume":"50 1","pages":"235 - 237"},"PeriodicalIF":0.1000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Scientific Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jss.jss_210_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Multisystem inflammatory syndrome in children (MIS-C) is a postviral complication that has been described among children after 2–6 weeks of exposure to the COVID-19 virus from various parts of the world. Published literature regarding MIS-C in children is limited. The aim of this study was to investigate the disease management and clinical outcomes of a larger group of children from North India presenting with features of MIS-C. Materials and Methods: This is an observational study of children with MIS-C, admitted to the pediatric intensive care unit (PICU) between March 1, 2021, and August 31, 2021, during the second wave of SARS-CoV-2 infection in India. Results: Out of the 37 children presenting with MIS-C, 62% of patients were male and 37% were female patients. Vasoactive medications were required in 14 patients. Eighteen patients required respiratory support, of which 17 received noninvasive ventilation and only one patient required invasive mechanical ventilation. Methylprednisolone and intravenous immunoglobulin (IVIG) were used in the majority of patients. No patient required remdesivir. Thirty-six patients were discharged home with a median duration of 4 days in PICU and a hospital stay of 10 days, only 1 (2.7%) patient died during the treatment. Thirty-five (94.5%) patients received IVIG alone, and five patients (13.5%) received IVIG along with methylprednisolone. Patients who received a combination of steroids and IVIG had greater severity of illness, deranged laboratory parameters, highly raised inflammatory markers, requiring higher inotropes, respiratory support, PICU requirement, and length of stay in hospital. Conclusions: The decision to treat MIS-C patients with IVIG plus methylprednisolone or IVIG alone must be reviewed on an individual basis. IVIG in conjunction with methylprednisolone should be considered for patients with severe MIS-C and hypotension who have been admitted to the PICU.
儿童多系统炎症综合征的治疗反应和短期预后
背景:儿童多系统炎症综合征(MIS-C)是一种病毒后并发症,已在世界各地接触新冠肺炎病毒2-6周后的儿童中进行了描述。已发表的关于儿童MIS-C的文献有限。本研究的目的是调查来自北印度的一大群具有MIS-C特征的儿童的疾病管理和临床结果。材料和方法:这是一项针对2021年3月1日至2021年8月31日期间在印度第二波严重急性呼吸系统综合征冠状病毒2型感染期间入住儿科重症监护室(PICU)的MIS-C儿童的观察性研究。结果:在37名出现MIS-C的儿童中,62%的患者为男性,37%为女性。14名患者需要使用血管活性药物。18名患者需要呼吸支持,其中17名患者接受了无创通气,只有一名患者需要有创机械通气。大多数患者使用甲基泼尼松和静脉注射免疫球蛋白(IVIG)。没有患者需要瑞德西韦。36名患者出院回家,在PICU的中位持续时间为4天,住院时间为10天,只有1名(2.7%)患者在治疗期间死亡。35名(94.5%)患者单独接受IVIG治疗,5名(13.5%)患者接受IVIG和甲基强的松龙治疗。接受类固醇和IVIG联合治疗的患者病情更严重,实验室参数紊乱,炎症标志物高度升高,需要更高的止痛药、呼吸支持、PICU要求和住院时间。结论:使用IVIG联合甲基强的松龙或单独使用IVIG治疗MIS-C患者的决定必须根据个人情况进行审查。对于已入住PICU的严重MIS-C和低血压患者,应考虑IVIG联合甲基强的松龙。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the Scientific Society
Journal of the Scientific Society MEDICINE, GENERAL & INTERNAL-
自引率
33.30%
发文量
19
审稿时长
36 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信